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Objectives: A number of systemic variables are associated with infrainguinal graft failure and also with experimental 
smooth muscle hyperplasia. Stenosis is the most common cause of infrainguinaI graft thrombosis but it is not known if 
systemic variables are associated with stenosis. 
Design, materials and methods: In this study, clinical and serological factors were measured and correlated with stenosis 
development in 8i infrainguinal bypass grafts (52 vein, 29 PTFE; 28 with stenosis) in prospective (n = 46) and 
retrospective (n= 35) groups. Pre-existing stenosis was excluded by perioperative graft assessment. 
Results: There was a significantly greater proportion of. smokers in the patients who developed stenosis (11/18; 61%) 
compared with those who did not (6/28; 21%, p = 0.006; ~2). Patients who developed stenosis also had significantly (Mann 
Whitney U-tests), higher circulating levels of [median (interquartile range)] fibrinogen (412.5 (356-484.5) vs. 339 
(300-397.7) mg/IOOml, p=O.O03), Lipoprotein (a) (0.20 (0.05-0.45) vs. 0.085 (0.05-0.23) g/l, p=O.03) and 
5-hydroxytryptamine (14.1 (6.6-45) vs. 4.41 (3-8.39) nmol/l, p = 0.005), than those without stenosis. 
By logistic regression, these associations were independent ofgraft material and whether grafts were studied prospectively 
or retrospectively. 
Conclusions: Smoking and plasma fibrinogen, Lp(a) and 5-hydroxytryptamine ar markers for postoperative infrainguinal 
graft stenosis. 
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Introduction 
A number of patient related variables, notably smok- 
ing, hyperfibrinogenaemia and hyperlipidaemia have 
been shown to be associated with reduced patency 
after arterial reconstruction. 1~ 
In vitro and animal studies of intimal hyperplasia 
and atherogenesis have demonstrated the potential of 
tobacco smoke derivatives, 5-8 coagulation cascade 
proteins, 9-12 cholesterol and apolipoproteins 13q5 and 
platelet releasates 16qs to stimulate proliferation of 
smooth muscle cells. Migration and proliferation of 
medially derived smooth muscle cells produces vessel 
19 20 wall thickening after arterial reconstruction ' and 
results in localised stenosis in approximately 25% of 
infrainguinal bypass grafts. 2~'22 The adverse haemo- 
dynamic consequences of stenosis are believed to 
cause up to 80% of infrainguinal graft thrombo- 
ses. 21'23'24 Thus, clinical and serological variables may 
influence graft stenosis development. 
*Please address all correspondence to N. J. Cheshire. 
In this study we measured a number of factors, all 
of which are associated either with increased risk of 
failure after arterial reconstruction or experimental 
proliferation of smooth muscle cells (both in most 
cases) and compared these in patients who did or did 
not develop hyperplastic stenosis in infrainguinal 
bypass grafts. 
Methods 
Ethical committee approval was granted for this 
study. 
Patients 
Clinical and serological variables were measured in 81 
patients undergoing infrainguinal bypass grafting 
under the care of a single surgeon. Autologous vein 
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conduits were used in 52 bypasses and the remaining 
29 were 6mm expanded polytetrafluoroethylene 
(PTFE) grafts (Impra U.K.). There were 53 femor- 
opoplitea125grafts and 28 femorocrural grafts. A distal 
vein collar was used with prosthetic grafts to crural 
vessels. 
Patients were recruited in two groups. The pro- 
spectively followed group consists of 46 consecutive 
patients (30 autologous vein and 16 PTFE grafts) who 
underwent arterial reconstruction during the study 
period. Variables were measured immediately prior to 
arterial reconstruction i all cases. Median follow-up 
is 17.5 months with a minimum follow up of 12 
months. 
The retrospective study group consists of 35 
patients (22 autologous vein and 13 PTFE grafts) in 
whom risk factors were measured a mean of 10 
months (standard eviation +/ -  5) after reconstruc- 
tion. These patients were recruited randomly from 
those attending for graft follow up during the study 
period. All had undergone infrainguinal reconstruc- 
tion by the same surgeon and had standardised 
Duplex surveillance data recorded. Entry criteria 
included perioperative assessment, a patent graft 
which had not undergone thrombectomy or thrombol- 
ysis and completion of at least 1 year of surveillance 
(described below). 
Exclusion of non-hyperplastic graft stenoses 
All patients included in this study underwent intra- 
operative Doppler studies 26 and predischarge Duplex 
scanning to exclude fixed, non hyperplastic causes of 
graft stenosis uch as retained valve cusps, intramural 
venous disease or anastomotic technical error. Steno- 
ses identified intraoperatively were corrected uring 
primary reconstruction and results confirmed with 
arteriography. 
Graft surveillance and stenosis detection 
Following discharge, patients underwent Duplex 
scanning at 6 weeks, and 3, 6, 9 and 12 months post- 
reconstruction using the V2:V1 technique. 27 Severe 
stenoses (V2:V1 > 2 on Duplex), confirmed by angiog- 
raphy were corrected by percutaneous balloon dilata- 
tion, patch angioplasty or jump grafting. 
For the purposes of this study graft stenosis is 
defined as a new stenosis detected within the first 
postoperative year, requiring correction. Non-sten- 
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osed grafts are those which remained patent and have 
undergone regular surveillance for at least 1 post- 
operative year, during which no stenosis was 
detected. 
Risk factor measurement 
The clinical and serological variables measured in this 
study have all been shown to be associated either with 
increased risk of failure after arterial reconstruction or
experimental proliferation of smooth muscle cells and 
are shown in Table 1. 
It was not possible to measure all risk factors in all 
patients; assessment of smoking and hypertension 
relevant o the time of stenosis development was only 
possible in the prospective group. In addition to blood 
samples invalidated for technical reasons, patients 
were required to travel between two hospitals (St 
Mary's and The Royal Free) for laboratory analysis. 
Although this policy minimised error caused by in 
vitro changes due to delay in analysis, inevitably some 
patients were unable to attend both hospitals. It is 
appreciated that these losses may increase the like- 
lihood of statistical error, but the selection of patients 
was not subject to influence by the authors. The 
numbers of patients tudied in each group is shown in 
the relevant results section. 
Clinical risk factors Smoking was assessed by direct 
questioning and validated by measurement of breath 
Carbon Monoxide (CO) concentration using the 
Microsmokalyser (Bedfont Scientific, Upchurch, Kent, 
U.K.). Readings above 10 ppm expired CO were 
considered indicative of current smoking as recom- 
mended by the manufacturer. 
Hypertension was defined as current use of one or 
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more anti-hypertensive agents to maintain normal 
blood pressure and diabetes mellitus as current diet, 
oral or insulin therapy for control of serum glucose. 
Lipids and Iipoproteins Whole blood was collected from 
an antecubital vein after a minimum 12 h fast and 
stored in plain tubes. Serum was prepared by centrifu- 
gation at 3000 × g. 
Serum cholesterol and triglycerides were deter- 
mined enzymatically using a Centrifichem centrifugal 
analyser (Baker Instruments, Windsor, U.K.), Low 
density lipoprotein (LDL) cholesterol was calculated 
by the Friedwald equation. 28 High density lipoprotein 
(HDL) was isolated by the dextran sulphate-Mg C12 
method 29 and the cholesterol measurement performed 
as above. Apolipoproteins were measured using 
imrnunonephelometry (Beckman Auto Immuno- 
Chemical Systems, Beckman Instruments, High 
Wycombe, U.K.) 
Platelet function Blood was taken from an antecubital 
vein with minimal stasis. For aggregation studies, nine 
parts of blood were added to one part of 3.8% w/v  
trisodium citrate (BDH, Poole, Dorset, U.K.). For 
measurement of platelet release substances, citrated 
blood containing indomethacin (20 mg/1), theophyl- 
line (3mmol/1) and adenosine (lmmol/1) was 
prepared. 
Plasma was prepared by centrifuging blood for 20 
min at 1500 × g at 4°C. The supernatant was collected 
and spun again as above and kept frozen at -40°C. 
Platelet rich plasma (PRP) was prepared using the 
technique described by Hardisty et al. 3° Nine volumes 
of venous blood were collected in a polystyrene 
syringe and mixed with one part 3.8% trisodium 
citrate in a polystyrene tube. PRP was prepared by 
centrifuging blood at 160 ×g for 15 rain at room 
temperature. 
Platelet counts were performed using a Coulter 
T-890 blood counter (Coulter Electronics, Luton, U.K.). 
Following counting, the PRP was centrifuged at 
1000 × g for 10 min to prepare platelet pellets. The 
pellets were washed with Isoton II (Coulter Electron- 
ics, Luton, U.K.) and stored at -40°C until analysis. 
Whole blood aggregation was evaluated by a free 
platelet count method using a blood cell counter 
(Coulter %890; see above). 
Plasms Platelet Serotonin and fi-thromboglobulin assay 
Platelet pellets were resuspended in physiological 
saline (0.9% w/v) and platelets lysed using the MSE- 
Soniprep sonicator (MSE, Sussex, U.K.). Plasma ser- 
otonin (5-hydroxytrptamine; 5-HT) concentrations 
were estimated using a radioimmunoassay (Biogene- 
sis Ltd., Bournemouth, U.K.). 
Coagulation and fibrinolytic activity Blood was collected 
from an antecubital vein with minimal stasis and 
anticoagulated with 3.8% trisodium citrate in propor- 
tions of 9:1, respectively, in precooled tubes. Samples 
were centrifuged at 3000 × g for 15 rain at 4°C and 
plasma was stored at -70°C until analysis. 
Levels of plasma fibrinogen and plasminogen and 
activity of factors VII and VIII (percentage activity 
relative to standardised plasma) were assayed using 
an automated coagulation analyser (ACL 300 
Research; Instrumentation Laboratory Ltd, Warring- 
ton, Cheshire, U.K.). 
For the quantitative determination f tissue plasmi- 
nogen activator (t-PA) citrated blood was collected in 
concentrations of nine parts blood to one part 3.8% 
trisodium citrate as described above. Samples were 
processed as recommended by Chandler et al. 31 For 
the quantitative determination f plasminogen activa- 
tor inhibitor (PAI-1) concentration, blood was col- 
lected into citrate as already described, supplemented 
with the following anti-platelet agents: indomethacin 
(20 rag/1 final concentration F.C.), theophylline (F.C. 
3mmol/1) and adenosine (F.C. 1 mmol/1), t-PA and 
PAI-1 antigen were quantitated using Enzymoimmu- 
noassay Kits (Kabi Diagnostica, Sweden). 
Statistical analysis 
The data was analysed with help from Mrs. Jane 
Wadsworth in the Academic Department of Public 
Health at St.Mary's Hospital Medical School. 
This study compares a number of variables between 
patients who developed graft stenosis and those who 
did not; it was considered important o include the 
influence of study groups (retrospective or pro- 
spective) and graft type (vein or PTFE) on the 
comparison. A two part analysis was therefore used; 
primary examination of all data by univariate analy- 
sis, followed by logistic regression of those factors 
associated with stenosis also including the effects of 
prospective and retrospective groups and vein and 
PTFE grafts. 
The Chi-square and Mann-Whitney U tests were 
used for univariate analysis. Results are presented as 
median and interquartile range with individual data 
points shown on figures. 
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Table 2. Clinical risk factor profiles in prospectively studied 
patients (n=46) 
Stenosed Non-stenosed p= (X 2 test) + 
grafts grafts Yates' Correction 
Diabetes mellitus 3/18 5/28 0.91 
Hypertension 8/18 13/28 0.89 
Smoking 11/18 6/28 0.016 
Female sex 6/18 7/28 0.54 
Results 
Stenosis rates and histological assessment 
During follow-up in the prospective group of patients, 
graft stenoses requiring intervention were detected in 
12/30 vein grafts (40%) and 6/16 PTFE grafts (37.5%). 
Twenty-eight grafts remained stenosis free during a 
minimum of 1 year surveillance. 
In the retrospective group, 10 patients (five each 
vein grafts and PTFE grafts) had developed graft 
stenosis requiring correction during the first post- 
operative year and 25 patients were stenosis free. 
Tissue from stenoses was obtained from 12 patients 
treated by excision or patch angioplasty (other cases 
were corrected by percutaneous angioplasty or jump 
grafting). Histology confirmed intimal thickening due 
to smooth muscle hyperplasia in all cases. 
Clinical variables 
Comparison of clinical variables between patients 
who did and did not develop stenosis was only 
undertaken on the prospective group to reflect circum- 
stances at the time of stenosis development. Table 2 
compares the clinical risk factor profiles of pro- 
spectively studied patients who did and did not v00 
develop stenosis. 650 
By univariate analysis, a significantly greater pro- ~ 6oo 
portion of patients who developed stenosis continued ~550 
to smoke after reconstruction; stenosis group S 500 
11/18(61%) compared with 6/28 (21%) in the non ~45o 
stenosis, p -- 0.006, X2 test (p = 0.016 after Yates Correc- .~ 40o 
tion) see Fig. 1. ~ 850 
Regression analysis showed that smoking differ- ~ 3oo 
ences between the two groups were independent of ~ 25o 
the graft material (maximum likelihood estimates; G 2oo 
smokers vs. non-smokers, --2.507 p = 0.0007: vein vs. 150 
PTFE, 0.286 p = 0.707). 
Clotting and fibrinolysis studies 










Patients who developed 
graft stenosis 
Fig. 1. Bar chart showing patients who continued to smoke after 
reconstructioon as a proportion of patients who did and did not 
develop graft stenosis. ( )  smokers; (~) non-smokers. 
available for 53 patients (21 stenosed and 32 non 
stenosed grafts). The plasma concentration of fibrino- 
gen was significantly higher in patients with grafts 
which developed stenosis (413 (356-4845) vs. 339 
(300-398) mg/100ml, p= 0.003, Mann Whitney U test, 
Fig. 2). By regression analysis, these differences were 
independent of graft material or study group (max- 
imum likelihood estimates: fibrinogen, -0.0163 
p = 0.0013: vein vs. PTFE, 0.2053 p = 0.7: prospective vs. 
retrospective, -1.239 p = 0.08). 
There were no significant differences in activity of 
factors VII or VIII, tPA or PAI-1 or plasminogen 
concentration between stenosed and non stenosed 
grafts (results not shown). 
000 
- • 
000  • 
p=O.O03 
Mann-Whitney 
Patients with Patients without 
graft stenosis graft stenosis 
Fig. 2. Scattergram showing plasma fibrinogen concentration n vein 
and PTFE grafts which developed stenosis and those that did not. 
The bar shows median fibrinogen concentration. 
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Fig. 3. Scattergram showing serum lipoprotein (a) concentration n 
vein and PTFE grafts which developed stenosis and those that did 
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Patients with Patients without 
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Fig. 4. Scattergram showing plasma 5-HT concentration n vein and 
PTFE grafts which developed stenosis and those that did not. The 
bar shows median 5-HT concentration. 
Lipids and lipoproteins 
Results of l ipid/lipoprotein analysis were available 
for fifty patients (20 stenosed and 30 non stenosed 
grafts). Median serum concentration of lipoprotein (a) 
was higher in patients whose grafts developed sten- 
osis than those who did not (0.20 (0.05-0.45) vs. 0.085 
(0.05-0.23) g/l ,  p = 0.03 Mann Whitney test, Fig. 3). By 
regression analysis, these differences were independ- 
ent of graft material or study group (maximum 
likelihood estimates: Lp(a) -1.518 p =0.04, vein vs. 
PTFE 0.128 p = 0.8, prospective vs. retrospective 0.335 
p = 0.6). 
There were no significant differences in levels of 
triglycerides, cholesterol, HDL, LDL or apolipopro- 
teins A or B between the two groups (results not 
shown). 
Plasma serotonin and platelet function studies 
Results of platelet function analysis were available for 
47 patients (20 stenosed and 27 non-stenosed grafts). 
Plasma 5-HT concentration was higher in patients 
who developed stenosis compared with those who did 
not (14.1 (6.6-45) vs. 4.4 (3--8.39) nmol/1 p=0.005, 
Mann Whitney test, Fig. 4). By regression analysis, 
these differences were independent of graft material 
or study group (maximum likelihood estimates: 5HT 
1.822 p = 0.018, vein vs. PTFE 0.099 p = 0.8, prospective 
vs. retrospective 0.691 p = 0.3). 
By univariate analysis, there were differences in 
platelet aggregation between stenosed and non-sten- 
osed grafts when adrenalin was used as an agonist but 
these failed to remain significant when the effects of 
graft material and study group were included in the 
regression analysis. There were no other significant 
differences in platelet aggregation or plasma and 
intraplatelet levels of releasates between those 
patients who developed stenosis and those who did 
not. 
Discuss ion  
Haemodynamically significant stenoses develop in 
approximately 25% of infrainguinal bypass grafts, 
usually within the first 12 months after surgery al and 
may be associated with up to 80% of postoperative 
graft thromboses. 23 This has led to the establishment 
of stenosis urveillance and correction programmes in
many vascular surgical centres. Reported stenosis 
rates are often higher from centres with an interest in 
graft surveillance and this is borne out by the 
prospective finding of stenoses in 37.5% of PTFE and 
40% of autologous vein grafts in the current series. 
Histological examination of stenoses from both vein 
and prosthetic grafts reveals similar pathology; a 
localised, subintimal proliferation of smooth muscle 
cells with a surrounding matrix of proteoglycan and 
collagen. 32 Although the sequence of events leading to 
this intimal hyperplasia is now understood 18'33'34 the 
stimuli responsible for smooth muscle cell migration 
to the subintima and their subsequent proliferation, 
remain unclear. 
A number of recent publications have identified 
clinical and serological variables associated with 
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increased failure rates after arterial reconstruction 2~'35 
and there is overlap between these factors and those 
known to stimulate smooth muscle cell proliferation 
in experimental models. 9'10'12'16'36-39 This suggests that 
the observed increase in graft failure rates associated 
with these risk factors may be a consequence of 
increased stenosis development. 
In the present study we have demonstrated an 
association between stenosis of infrainguinal bypass 
grafts and plasma levels of lipoprotein (a), fibrinogen 
and serotonin as well as an increased incidence of 
smoking. These results have two potentially important 
implications. As preoperative markers of graft sten- 
osis, these variables may be of value in identifying 
patients and grafts at increased risk of developing 
stenosis and thus thrombosis. This could be used to 
target a more aggressive and potentially more cost 
effective graft surveillance programme. Secondly, the 
data supports a large body of circumstantial evidence 
suggesting a causative relationship between circulat- 
ing factors and hyperplasia of mural smooth muscle 
cells in both graft intimal hyperplasia nd in athero- 
sclerosis. This is important as it infers that correction 
of risk factors may reduce the incidence of stenosis. It 
is of value therefore to review the data implicating the 
above variables in experimental smooth muscle cell 
mitosis. 
Tobacco smoking is one of the major risk factors for 
atheroma development in man since it accelerates 
atherosclerosis in both the peripheral and coronary 
circulation. 4°'41 The mechanism of action is unknown, 
but hypothetical mechanisms include vessel injury 
through vasospasm, hypoxia or endothelial cell 
loss 7'42'43 and platelet activation. 44'45 Smoking-related 
endothelial injury in an infrainguinal graft and the 
perianastomotic vessels (perhaps exacerbated by oper- 
ative trauma) could expose medial smooth muscle 
cells to a variety of mitogens both in the plasma and in 
platelets (perhaps activated by smoking), resulting in 
the development of a localised proliferative lesion in a 
similar manner to that proposed in the early genesis of 
atheroma. 46This could explain the observations in the 
current study and suggests a possible causal 
relationship. 
Fibrinogen is the soluble precursor of fibrin. Epide- 
miological studies have demonstrated that elevated 
levels of circulating fibrinogen are associated with 
accelerated evelopment of atheroma nd coronary 
4748 events in man. ' Cell culture studies have shown 
that fibrinogen and its derivatives are chemotactic and 
mitogenic to smooth muscle cells. 11"12"49 Despite this, it 
is still unclear whether the observed adverse cardio- 
vascular effects of hyperfibrinogenaemia aremediated 
through a hypercoaguable state or at the vessel wall 
level. The present findings show fibrinogen to be 
associated with infrainguinal graft disease in the 
absence of overt thrombosis. Additionally, there were 
no differences in plasma levels of other coagulation or 
fibrinolytic factors between patients with and without 
stenosis and this suggests that in infrainguinal bypass 
grafts, fibrinogen acts via a mechanism independent 
of the coagulation cascade. 
Lipoprotein (a) is a protein-lipid complex, similar in 
composition to LDL but containing apolipoprotein (a). 
Attention has been focused on this molecule since it 
was shown to be an independent predictive factor for 
the development of atheroma in man. 5°'~1 Its mecha- 
nism of action is unclear; circulating Lp(a) may affect 
the vessel in similar ways to those proposed for other 
atherogenic lipoproteins (increasing endothelial per- 
meability to lipids or by oxidisation and direct 
stimulation of smooth muscle mitosis). However, 
apo(a) also has structural similarity to plasminogen 52
and can compete with plasminogen and t-PA for 
fibrinogen binding in vitro 53"54 and may thus possess 
pro-coagulant properties. Our observation that there 
were no differences in plasminogen or t-PA activity 
between stenosed and non stenosed groups of patients 
suggests that the association between Lp(a) and 
infrainguinal graft stenosis is independent of coagula- 
tion effects but interpretation of these results is 
difficult as fibrinogen levels also varied between 
patient groups. 
Platelets are excellent candidates as initiators of 
intimal hyperplasia s they are known to contain at 
least two mitogens for vascular smooth muscle cells- 
--platelet derived growth factor (PGDF) 16 and epi- 
dermal growth factor (EGF) 55-  both of which are 
released uring activation. As well as being mitogenic, 
PGDF is also a chemotactic agent for smooth muscle 
cells 56 and at least in theor)~ could induce both smooth 
muscle cell migration from the media and subsequent 
subintimal proliferation. Epidemiological evidence 
suggests an association between platelet activation 
and the development of atherosclerosis 57-61 and ani- 
mal studies have demonstrated increased intimal 
thickening in bypass grafts with high levels of labelled 
platelet adherence 39as well as the protective ffects of 
anti-platelet therapy. 62'63 In excess of 99% of whole 
blood 5-HT is contained within the dense granules of 
platelets in humans and a number of studies have 
demonstrated that platelet degranulation is associated 
with elevation of the plasma 5-HT level. 64-66 5-HT has 
also been shown to possess mitogenic properties and 
to significantly enhance the mitogenic properties of 
PDGF. 67 The data presented above may demonstrate 
an association between platelet activation and the 
development ofgraft stenosis. However, other sources 
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of 5HT (most importantly endothelial cells) may 
contribute to circulating levels making interpretation 
of plasma results difficult. Because we were unable to 
demonstrate other evidence of platelet activation in 
association with graft stenosis we believe that the 
current data is insufficient o show a conclusive 
association between platelet activation and infra- 
inguinal graft stenosis. 
The present study demonstrates that cigarette 
smoking, plasma fibrinogen, Lp(a) and 5-HT are 
markers for the postoperative d velopment of stenosis 
in infrainguinal bypass grafts. These variables are 
known to be associated with the proliferation of 
smooth muscle cells in experimental models and have 
been indirectly associated with increased rates of 
failure after arterial reconstruction suggesting that 
they may be associated with increased smooth muscle 
cell mitosis in the graft wall. A randomised study of 
the effects of perioperative correction of these 'risk' 
factors on the incidence of graft stenosis may be 
justified. 
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